Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Camptothecins in clinical development.

Franco Zunino1, Graziella Pratesi

  • 1Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy. franco.zunino@istitutotumori.mi.it

Expert Opinion on Investigational Drugs
|March 12, 2004
PubMed
Summary

Camptothecins are key DNA topoisomerase I inhibitors. Researchers are developing new analogues to overcome limitations of existing drugs like topotecan and irinotecan, aiming for improved therapeutic benefits.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Timely deployment of best-in-class technologies to enable development and decarbonise construction.

Nature communications·2025
Same author

Is there a future for <sup>43</sup>Ca nuclear magnetic resonance in cement science?

Physical chemistry chemical physics : PCCP·2025
Same author

EVALUATING THE HYDRATION OF HIGH VOLUME FLY ASH MIXTURES USING CHEMICALLY INERT FILLERS.

Construction and building materials·2024
Same author

Performance of cementitious systems containing calcined clay in a chloride-rich environment: a review by TC-282 CCL.

Materials and structures·2024
Same author

Stabilization of c-KIT G-Quadruplex DNA Structures by the RNA Polymerase I Inhibitors BMH-21 and BA-41.

International journal of molecular sciences·2019
Same author

Reducing setting time of blended cement paste containing high-SO<sub>3</sub> fly ash (HSFA) using chemical/physical accelerators and by fly ash pre-washing.

Cement & concrete composites·2018

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • DNA topoisomerase I is a validated therapeutic target for cancer treatment.
  • Camptothecins are the only clinically relevant topoisomerase I inhibitors.
  • Existing camptothecins face challenges including poor solubility, instability, and drug resistance.

Purpose of the Study:

  • To provide an overview of novel camptothecin analogues in clinical development.
  • To highlight chemical modifications aimed at overcoming existing drug limitations.
  • To discuss the potential therapeutic advantages of new analogues.

Main Methods:

  • Review of chemical modifications of natural camptothecin.
  • Analysis of analogues in various stages of clinical development (water-soluble, lipophilic, polymer-bound).
  • Comparison of potential therapeutic benefits against approved analogues (topotecan, irinotecan).

Main Results:

  • Several novel camptothecin analogues are undergoing clinical trials.
  • Chemical strategies address issues like water insolubility and lactone instability.
  • New formulations aim to improve drug delivery and efficacy.

Conclusions:

  • Ongoing research focuses on enhancing camptothecin efficacy and safety.
  • Novel analogues may offer improved therapeutic profiles compared to current treatments.
  • Further clinical evaluation is necessary to define the advantages of these new agents.

Related Experiment Videos